Amgen (AMGN)

Biotech company Amgen (NASDAQ:AMGN) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 8.5% year on year to $10.37 billion. ...

Amgen (NASDAQ:AMGN) reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several late-stage programs. The company raised its full-year revenue and adjusted earnings outlook while highlight

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 8.5% year on year to $10.37 billion. The company’s fu...

The red-hot healthcare stock may soon have another catalyst that drives its value even higher.

Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp...

Amgen can appeal to various kinds of investors.

Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.

Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.

Both of these biotech stocks could be appealing to income investors.

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance treatment, improved survival outcomes for patients with extensive-stage small-cell lung cancer whose di

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?

The company's board of directors can play a vital role in positioning the company to develop the next generation of aircraft.